Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana
AstraZeneca PLC (NASDAQ:AZN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.
Astrazeneca Plc (AZN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 20,695,979 | $1,446,235,135 | +3% | 0.57% |
| 2. | Holocene Advisors Brandon Haley | 4,321,629 | $301,995,435 | -3% | 0.74% |
| 3. | 2,274,900 | $158,970,012 | +35% | 0.03% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,999,931 | $139,755,178 | +46% | 0.16% |
| 5. | D E Shaw D. E. Shaw | 1,904,943 | $133,117,417 | +13% | 0.09% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 41,200,091 | $2,879,062,356 | 2.28% | |
| 2. | 34,337,281 | $2,399,489,197 | 0.44% | |
| 3. | 31,404,983 | $2,194,439,575 | 0.38% | |
| 4. | 31,171,353 | $2,178,254,139 | 0.16% | |
| 5. | 21,341,718 | $1,491,359,196 | 0.08% |
News See All
11 Best GLP-1 and Weight Loss Stocks to Invest in
GLP-1 medicines are a type of prescription that mimics a natural hormone that regulates blood sugar and appetite.
AstraZeneca PLC (NASDAQ:AZN) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to AstraZeneca's H1 and Q2 2025 webinar for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
AstraZeneca Just Missed Estimates, but Here’s Why Bulls Aren’t Worried Yet
Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor letter. The fund focuses on owning a concentrated portfolio of U.S.
AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion
AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom.
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab
AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN) announced positive results for its global Phase 3 trial of Gefurulimab in...
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation
[caption id="attachment_1199068" align="aligncenter" width="1456"] A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism ...
Top 10 Safest Dividend Stocks in the UK
UK stocks have delivered a strong performance recently, with the FTSE 100 crossing the 9,000 mark for the first time and hitting record highs several times this year.